PE20240110A1 - Variantes de anticuerpos felinos - Google Patents

Variantes de anticuerpos felinos

Info

Publication number
PE20240110A1
PE20240110A1 PE2023001243A PE2023001243A PE20240110A1 PE 20240110 A1 PE20240110 A1 PE 20240110A1 PE 2023001243 A PE2023001243 A PE 2023001243A PE 2023001243 A PE2023001243 A PE 2023001243A PE 20240110 A1 PE20240110 A1 PE 20240110A1
Authority
PE
Peru
Prior art keywords
igg
seq
amino acids
constant region
constant domain
Prior art date
Application number
PE2023001243A
Other languages
English (en)
Spanish (es)
Inventor
Lisa Marie Bergeron
Henry Luis Campos
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of PE20240110A1 publication Critical patent/PE20240110A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PE2023001243A 2020-09-29 2021-09-29 Variantes de anticuerpos felinos PE20240110A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063084693P 2020-09-29 2020-09-29
PCT/US2021/052579 WO2022072446A1 (en) 2020-09-29 2021-09-29 Feline antibody variants

Publications (1)

Publication Number Publication Date
PE20240110A1 true PE20240110A1 (es) 2024-01-22

Family

ID=78599139

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2023001243A PE20240110A1 (es) 2020-09-29 2021-09-29 Variantes de anticuerpos felinos

Country Status (16)

Country Link
US (2) US12612455B2 (cg-RX-API-DMAC10.html)
EP (2) EP4221744A1 (cg-RX-API-DMAC10.html)
JP (1) JP2023542737A (cg-RX-API-DMAC10.html)
KR (1) KR20230091914A (cg-RX-API-DMAC10.html)
CN (1) CN116457369A (cg-RX-API-DMAC10.html)
AR (1) AR123645A1 (cg-RX-API-DMAC10.html)
AU (1) AU2021352395A1 (cg-RX-API-DMAC10.html)
CA (1) CA3195049A1 (cg-RX-API-DMAC10.html)
CL (2) CL2023000914A1 (cg-RX-API-DMAC10.html)
CO (1) CO2023004107A2 (cg-RX-API-DMAC10.html)
EC (1) ECSP23030307A (cg-RX-API-DMAC10.html)
IL (1) IL301414A (cg-RX-API-DMAC10.html)
MX (1) MX2023003694A (cg-RX-API-DMAC10.html)
PE (1) PE20240110A1 (cg-RX-API-DMAC10.html)
TW (3) TW202545990A (cg-RX-API-DMAC10.html)
WO (1) WO2022072446A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL301414A (en) 2020-09-29 2023-05-01 Zoetis Services Llc Feline antibody variants
WO2025166165A1 (en) * 2024-02-01 2025-08-07 Zoetis Services, Llc Compositions and methods for modifying antibody effector functions
WO2026136223A1 (en) * 2024-12-19 2026-06-25 Zoetis Services Llc Compositions and methods for improving feline antibody functions

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US5698762A (en) 1994-12-09 1997-12-16 Dauerman; Leonard Microwave-assisted pyrolysis of waste polyaromatic hydrocarbons
GB9601081D0 (en) * 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
US20030031671A1 (en) 2001-08-01 2003-02-13 Sydney Welt Methods of treating colon cancer utilizing tumor-specific antibodies
CN1961003B (zh) 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
CA2577133A1 (en) 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
US9200079B2 (en) 2004-11-12 2015-12-01 Xencor, Inc. Fc variants with altered binding to FcRn
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
KR101616758B1 (ko) * 2007-12-26 2016-04-29 젠코어 인코포레이티드 FcRn에 대한 변경된 결합성을 갖는 Fc 변이체
ES2665954T3 (es) 2010-08-19 2018-04-30 Zoetis Belgium S.A. Anticuerpos anti-NGF y su uso
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
US9617334B2 (en) 2012-06-06 2017-04-11 Zoetis Services Llc Caninized anti-NGF antibodies and methods thereof
WO2019113123A1 (en) * 2017-12-04 2019-06-13 Precithera, Inc. TGF-ß RECEPTOR FUSION PROTEINS AND OTHER TGF-ß ANTAGONISTS FOR REDUCING TGF-ß SIGNALING
EP3866842A4 (en) 2018-10-18 2022-07-13 Kindred Biosciences, Inc. FC VARIANTS WITH MODIFIED BINDING TO THE NEONATAL FC RECEPTOR (FCRN) FOR VETERINARY USE
WO2020116560A1 (ja) * 2018-12-05 2020-06-11 株式会社バイカ・セラピュティクス 抗体のFc領域改変体
EP4136109A1 (en) 2020-04-17 2023-02-22 Zoetis Services LLC Feline antibody variants
IL301414A (en) 2020-09-29 2023-05-01 Zoetis Services Llc Feline antibody variants
US20240400708A1 (en) 2020-12-18 2024-12-05 Zoetis Services Llc Mutations in feline antibody constant regions

Also Published As

Publication number Publication date
TWI814094B (zh) 2023-09-01
EP4221744A1 (en) 2023-08-09
EP4711383A2 (en) 2026-03-18
TW202413413A (zh) 2024-04-01
AU2021352395A1 (en) 2023-04-27
MX2023003694A (es) 2023-04-21
IL301414A (en) 2023-05-01
CL2023000914A1 (es) 2023-10-20
CA3195049A1 (en) 2022-04-07
CO2023004107A2 (es) 2023-04-27
CL2024000789A1 (es) 2024-07-19
KR20230091914A (ko) 2023-06-23
US20230382986A1 (en) 2023-11-30
TW202545990A (zh) 2025-12-01
TW202222830A (zh) 2022-06-16
ECSP23030307A (es) 2023-07-31
US12612455B2 (en) 2026-04-28
EP4711383A3 (en) 2026-04-29
AR123645A1 (es) 2022-12-28
WO2022072446A1 (en) 2022-04-07
US20260193335A1 (en) 2026-07-09
JP2023542737A (ja) 2023-10-11
TWI880316B (zh) 2025-04-11
CN116457369A (zh) 2023-07-18

Similar Documents

Publication Publication Date Title
PE20230348A1 (es) Variantes de anticuerpos felinos
PE20230108A1 (es) Variantes de anticuerpos caninos
JP2023522030A5 (cg-RX-API-DMAC10.html)
Thomson et al. A simplified method for the efficient refolding and purification of recombinant human GM-CSF
PE20242297A1 (es) Anticuerpo anti-ctla-4
AR086982A1 (es) Eliminacion de celulas diana por parte de celulas t citotoxicas especificas de virus utilizando complejos que comprenden mhc de clase i
PE20191436A1 (es) Metodos mejorados para estimular la productividad de anticuerpos en el cultivo de celulas de mamiferos y reducir la agregacion durante los procesos de formulacion post-tratamiento (downstream) y formulaciones de anticuerpos estables obtenidas a partir de los mismos
BR112015000798A2 (pt) heterodímeros assimétricos biespecíficos compreendendo construtos anti-cd3
EA201690299A1 (ru) СТАБИЛИЗАЦИЯ Fc-СОДЕРЖАЩИХ ПОЛИПЕПТИДОВ
JP2017512063A5 (cg-RX-API-DMAC10.html)
PE20091382A1 (es) Anticuerpos que se une a il-4 y/o a il-13
PE20191033A1 (es) PROTEINAS DE FUSION FC HETERODIMERICAS IL 15/IL 15R(alfa)
EA201591407A1 (ru) Антитела, содержащие химерные константные домены
AR109264A1 (es) Proteínas de unión semejantes a anticuerpo biespecíficas que se unen específicamente a cd3 y cd123
AR046833A1 (es) Anticuerpos anti-interleuquina-10
JP2016526909A5 (cg-RX-API-DMAC10.html)
EA200700751A1 (ru) Способы и композиции для улучшения продуцирования рекомбинантного белка
EA201691304A1 (ru) АНТАГОНИСТЫ НЕОНАТАЛЬНЫХ Fc-РЕЦЕПТОРОВ (FcRn) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
JP2017509335A5 (cg-RX-API-DMAC10.html)
FI3998285T3 (fi) Cd38:aan ja pd-l1:een sitoutuvia molekyylejä
PE20220489A1 (es) Anticuerpos de receptor de peptido natriuretico 1 y metodos de uso
PE20200738A1 (es) Tratamiento con obinutuzumab nuevo subgrupo de pacientes con nuevo linfoma de celulas b grandes difusas (dlbcl)
MY198370A (en) Proteins specific for baff and b7rp1
JP2023542737A5 (cg-RX-API-DMAC10.html)
AR123636A1 (es) Variantes de anticuerpos caninos